Latest Breaking News On - Fixed duration ibrutinib plus venetoclax - Page 1 : comparemela.com

Phase 3 GLOW: first-line ibrutinib plus venetoclax improves outcomes in elderly or unfit CLL

Phase 3 GLOW: first-line ibrutinib plus venetoclax improves outcomes in elderly or unfit CLL
physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomTalha munir leedsObinutuzumab clbAmerican society of hematologyAmerican society of hematology annual meetingAmerican societyTalha munirLeeds teaching hospitalsProspective dataMinimal residual diseaseFixed duration ibrutinib plus venetoclaxVersus chlorambucil plus obinutuzumabFirst line treatmentUnfit patientsHematology annual

Johnson & Johnson : New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrated Deeper and Sustained Undetectable Minimal Residual Disease Outcomes in First-Line Chronic Lymphocytic Leukemia

Updated results from the MRD cohort of the Phase 2 CAPTIVATE study also highlight potential for treatment-free remissions with IMBRUVICA® plus venetoclax in an oral presentation at ASH. | December 11, 2021

United statesCraig tendlerObinutuzumab clbBernadette kingJessica mooreChristie corbettJanssen biotech incAmerican society of hematology annual meetingEuropean hematology associationJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonAmerican society of hematologyAmerican society of clinical oncology annual meetingVirtual congressGlobal head of late development